Ramtin Agah Biography and Net Worth

Insider of RenovoRx

Dr. Agah has served as our Chief Medical Officer and Co-Founder since December 2009, and as Chairman of the Board since May 2018. Dr. Agah is currently an Interventional Cardiologist at El Camino Hospital, Mountain View, a role he began in September 2005. He also has acted as a physician consultant for Abbott Vascular since July 2012. Previously, Dr. Agah was an Assistant Professor of Internal Medicine with the Division of Cardiology, University of Utah. Dr. Agah completed a Fellowship in Interventional Cardiology with Cleveland Clinic Foundation, a Residency in Internal Medicine with Baylor College of Medicine and a Fellowship in Cardiology with University of California, San Francisco. He received his MD from the University of Texas Southwestern Medical School.

What is Ramtin Agah's net worth?: The estimated net worth of Ramtin Agah is at least $1.36 million as of January 21st, 2026. Agah owns 798,460 shares of RenovoRx stock worth more than $1,357,382 as of September 18th. This net worth approximation does not reflect any other assets that Agah may own. Learn More about Ramtin Agah's net worth.
How do I contact Ramtin Agah?: The corporate mailing address for Agah and other RenovoRx executives is 2570 W. EL Camino Real, Ste. 320,, Mountain View, CA, 94040. RenovoRx can also be reached via phone at (408) 800-2649 and via email at [email protected]. Learn More on Ramtin Agah's contact information.
Has Ramtin Agah been buying or selling shares of RenovoRx?: Ramtin Agah has not been actively trading shares of RenovoRx during the last quarter. Most recently, on Wednesday, January 21st, Ramtin Agah bought 10,000 shares of RenovoRx stock. The stock was acquired at an average cost of $1.00 per share, with a total value of $10,000.00. Following the completion of the transaction, the insider now directly owns 798,460 shares of the company's stock, valued at $798,460. Learn More on Ramtin Agah's trading history.
Who are RenovoRx's active insiders?: RenovoRx's insider roster includes Ramtin Agah (Insider), Laurence Marton (Director), and Mark Voll (CFO). Learn More on RenovoRx's active insiders.
Are insiders buying or selling shares of RenovoRx?: In the last year, RenovoRx insiders bought shares 9 times. They purchased a total of 94,000 shares worth more than $79,993.85. The most recent insider tranaction occured on May, 19th when CFO Mark Voll bought 25,000 shares worth more than $19,750.00. Insiders at RenovoRx own 9.4% of the company. Learn More about insider trades at RenovoRx.
Information on this page was last updated on 5/19/2026.

Ramtin Agah Insider Trading History at RenovoRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/21/2026	Buy	10,000	$1.00	$10,000.00	798,460
12/31/2025	Buy	9,795	$0.86	$8,423.70	788,460
12/30/2025	Buy	205	$0.83	$170.15	778,665
12/16/2025	Buy	12,000	$0.85	$10,200.00	778,460
12/5/2025	Buy	10,000	$0.96	$9,600.00	766,460
11/24/2025	Buy	12,000	$0.80	$9,600.00	756,460
11/21/2025	Buy	10,000	$0.80	$8,000.00	744,460
6/5/2025	Buy	21,000	$1.40	$29,400.00	734,460
4/15/2025	Buy	15,000	$0.90	$13,500.00	1,113,460
4/11/2025	Buy	20,000	$0.80	$16,000.00	1,098,460
4/8/2025	Buy	26,000	$0.84	$21,840.00	1,048,460
6/7/2022	Buy	5,182	$1.93	$10,001.26	6,477

Ramtin Agah Buying and Selling Activity at RenovoRx

RenovoRx Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Today's Range

Now: $1.71

$1.67

$1.75

50 Day Range

MA: $1.35

$0.85

$2.52

2 Week Range

Now: $1.71

$0.70

$2.59

Volume

276,198 shs

Average Volume

459,346 shs

Market Capitalization

$77.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12